natgillin/translations-raw huggingface dataset:
In patients scheduled for major elective orthopaedic surgery with a pretreatment haemoglobin of &gt; 10 to ≤ 13 g/dl, epoetin alfa has been shown to decrease the risk of receiving allogeneic transfusions and hasten erythroid recovery (increased haemoglobin levels, haematocrit levels, and reticulocyte counts).
Dokazano je da epoetin alfa u bolesnika predviđenih za veliki elektivni ortopedski kirurški zahvat s razinom hemoglobina od &gt; 10 do ≤ 13 g/dl prije liječenja smanjuje rizik od primanja alogenih transfuzija i ubrzava eritroidni oporavak (povišene razine hemoglobina i hematokrita te broja retikulocita).
In patients susceptible to greater reductions in intravascular volume as described above, larger decreases in eGFR ( &gt; 30%) were sometimes seen, which subsequently improved, and infrequently required interruption of treatment with canagliflozin (see section 4.8).
U bolesnika koji su osjetljivi na veće redukcije intravaskularnog volumena, kao što je opisano iznad, ponekad su primijećena veća smanjenja eGFR ( &gt; 30%), uz naknadna poboljšanja, koja su manje često zahtijevala prekid liječenja kanagliflozinom (vidjeti dio 4.8).
In patients treated with Genvoya, 92% (46/50) achieved HIV-1 RNA &lt; 50 copies/mL.
Od bolesnika liječenih lijekom Genvoya, 92% (46/50) ih je postiglo razinu HIV-1 RNK &lt; 50 kopija/ml.
In patients undergoing surgery, timing of the first fondaparinux injection requires strict adherence in patients ≥75 years, and/or with body weight &lt; 50 kg and/or with renal impairment with creatinine clearance ranging between 20 to 50 ml/min.
U bolesnika podvrgnutih operaciji, a koji su stariji od 75 godina i/ili tjelesne težine &lt; 50 kg i/ili imaju oštećenje bubrega s klirensom kreatinina 20 - 50 ml/min, treba se strogo pridržavati pravilnog trenutka primjene prve injekcije.
In patients who become neutropenic (ANC &lt; 1.5 x 109/l) the ANC should be monitored closely and Kineret treatment should be discontinued.
U bolesnika u kojih se pojavi neutropenija (ABN &lt; 1,5 x 109/l) treba pomno nadzirati apsolutni broj neutrofila te prekinuti liječenje Kineretom.
In patients who experienced either febrile neutropenia, neutrophil count &lt; 500 cells/mm3 for more than one week, severe or cumulative cutaneous reactions or severe peripheral neuropathy during docetaxel therapy, the dose of docetaxel should be reduced from 100 mg/m2 to 75 mg/m2 and/or from 75 to
Bolesnicima koji razviju febrilnu neutropeniju, imaju broj neutrofila manji od 500 stanica/mm3 dulje od tjedan dana, razviju teške ili kumulativne kožne reakcije ili tešku perifernu neuropatiju tijekom liječenja docetakselom dozu docetaksela treba smanjiti sa 100 mg/m2 na 75 mg/m2 i/ili sa 75 mg/m2 na
In patients who experienced either febrile neutropenia, neutrophil count &lt; 500 cells/mm3 for more than one week, severe or cumulative cutaneous reactions or severe peripheral neuropathy during docetaxel therapy, the dose of docetaxel should be reduced from 100 mg/m2 to 75 mg/m2 and/or from 75 to 60 mg/m2.
Bolesnicima koji razviju febrilnu neutropeniju, imaju broj neutrofila manji od 500 stanica/mm3 dulje od tjedan dana, razviju teške ili kumulativne kožne reakcije ili tešku perifernu neuropatiju tijekom liječenja docetakselom, dozu docetaksela treba smanjiti sa 100 mg/m2 na 75 mg/m2 i/ili sa 75 mg/m2 na 60 mg/m2.
In patients whose creatinine clearance is  30 mL/min/1.73 m2, no dosage adjustment is necessary.
U bolesnika u kojih klirens kreatinina iznosi &gt; 30 ml/min/1,73 m2 nije potrebna prilagodba doze.
In patients with &lt; 3 months disease duration an increase in visual acuity of 13.3 and 10.0 letters was seen at Month 1; and 17.7 and 13.2 letters at Month 24 in BRIGHTER and CRYSTAL, respectively.
U bolesnika s trajanjem bolesti od &lt; 3 mjeseca u 1. mjesecu uočeno je povećanje vidne oštrine od 13,3 odnosno 10,0 slova; te od 17,7 odnosno 13,2 slova u 24. mjesecu u ispitivanjima BRIGHTER i CRYSTAL.
In patients with a baseline 6MWD &lt; 350 meters, the mean change in observed 6MWD from baseline to Week 48 was 68 meters better in the ataluren 10-, 10-, 20-mg/kg arm than in the placebo arm (p=0.0053).
U bolesnika s početnom vrijednosti udaljenosti prijeđene u 6 minuta &lt; 350 metara, srednja promjena zabilježene udaljenosti prijeđene u 6 minuta od početne vrijednosti do 48. tjedna bila je 68 metara bolja u skupini koja je primala ataluren 10-, 10-, 20-mg/kg nego u skupini koja je primala placebo (p=0,0053).
In patients with a baseline haemoglobin of &gt; 13 g/dl, the possibility that Retacrit treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded.
Kod bolesnika s početnom razinom hemoglobina &gt; 13 g/dl ne može se isključiti da je liječenje Retacritom povezano s povećanim rizikom od postoperativnog trombotičkog/vaskularnog događaja.
In patients with a cardiovascular history/risk factors, fluticasone furoate/vilanterol 92/22 micrograms resulted in a significantly lower annual rate of moderate/severe COPD exacerbations compared with vilanterol (adjusted mean annual rates of 0.83 and 1.18 respectively, 30% reduction (95% CI 16, 42%, p &lt; 0.001)).
U bolesnika s kardiovaskularnim bolestima u anamnezi/čimbenicima rizika za te bolesti, primjena flutikazonfuroata/vilanterola od 92/22 mikrograma rezultirala je značajno nižom godišnjom stopom umjerenih/teških egzacerbacija KOPB-a u odnosu na vilanterol (prilagođene srednje godišnje stope od 0,83 odnosno 1,18, smanjenje od 30% (95% CI 16, 42%, p &lt; 0,001)).
In patients with a creatinine clearance of &lt; 80 mL/min, who are also receiving potent CYP3A4 inhibitors, the dose interval of maraviroc should be adjusted to 150 mg once daily (see sections 4.4 and 4.5).
U bolesnika s klirensom kreatinina &lt; 80 ml/min koji istodobno primaju snažne inhibitore CYP3A4, interval doziranja maraviroka treba prilagoditi na 150 mg jedanput na dan (vidjeti dijelove 4.4 i 4.5).
In patients with an eGFR &lt; 60 mL/min/1.73 m2 or CrCl &lt; 60 mL/min, a higher incidence of adverse reactions associated with volume depletion (e.g., postural dizziness, orthostatic hypotension, hypotension) was reported, particularly with the 300 mg dose.
U bolesnika s eGFR &lt; 60 mL/min/1,73m2 ili s CrCl &lt; 60 mL/min, prijavljena je veća incidencija nuspojava povezanih s deplecijom volumena (npr. posturalna omaglica, ortostatska hipotenzija, hipotenzija), naročito u onih na dozi od 300 mg.
In patients with baseline ALT or AST &gt; 5 x ULN, treatment is not recommended.
Kod bolesnika s početnim vrijednostima ALT-a ili AST-a &gt; 5 x iznad gornje granice normale, ne preporučuje se liječenje lijekom RoActemra.
In patients with baseline eGFR ≥ 30 and &lt; 60 ml/min/1.73m2 these events were reported in 18.5 % and 9.3 % of patients with dapagliflozin 10 mg or placebo.
U bolesnika koji su na početku liječenja imali eGFR ≥ 30 i &lt; 60 ml/min/1,73m2, ovi događaji bili su zabilježeni kod 18,5 % bolesnika u skupini koja je primala 10 mg dapagliflozina naprema 9,3 % u skupini koja je primala placebo).
In patients with chronic renal impairment whose creatinine clearance is &lt; 30 ml/min and who are not receiving regularly scheduled haemodialysis, the recommended dose is reduced to either 1000 mg administered as a single infusion or 750 mg followed one week later by 375 mg (see section 5.2).
U bolesnika s kroničnim oštećenjem bubrega čiji je klirens kreatinina &lt; 30 ml/min i koji se redovito ne podvrgavaju hemodijalizi, preporučena doza se smanjuje na 1000 mg dalbavancina u obliku jednokratne infuzije ili 750 mg nakon koje tjedan dana kasnije slijedi doza od 375 mg (vidjeti dio 5.2).
In patients with CLCR &lt; 30 ml/min use is not recommended due to insufficient data.
U bolesnika s CLCR &lt; 30 ml/min ne preporučuje se koristiti zbog nedostatka podataka.
In patients with creatinine clearance &lt; 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.2 and 5.2).
U bolesnika s klirensom kreatinina &lt; 15 ml/min, ili u bolesnika na dijalizi, nema kliničkog iskustva stoga se primjena apiksabana ne preporučuje (vidjeti dijelove 4.2 i 5.2).
In patients with creatinine clearance &lt; 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.4 and 5.2).
U bolesnika s klirensom kreatinina &lt; 15 ml/min, ili u bolesnika na dijalizi, nema kliničkog iskustva stoga se primjena apiksabana ne preporučuje (vidjeti dijelove 4.4 i 5.2).
In patients with creatinine clearance &lt; 20 ml/min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
U bolesnika čiji je klirens kreatinina &lt; 20 ml/min zabilježeno je da se poluvrijeme eliminacije hidroklorotiazida povisi na 21 sat.
In patients with creatinine clearance &lt; 20 ml/min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
U bolesnika čiji je klirens kreatinina &lt; 20 ml/min, zabilježeno je da se poluvrijeme eliminacije hidroklorotiazida povisi na 21 sat.
In patients with end stage renal disease (ESRD) (CrCL &lt; 15 mL/min) or on dialysis, the use of Lixiana is not recommended (see sections 4.4 and 5.2).
Za bolesnike u završnom stadiju bubrežne bolesti (ESRD) (CrCL &lt; 15 ml/min) ili na dijalizi, primjena Lixiane se ne preporučuje (vidjeti dijelove 4.4 i 5.2).
In patients with end-stage renal disease (ESRD) (CrCl &lt; 10 ml/min) requiring haemodialysis, between dialysis tenofovir concentrations substantially increased over 48 hours achieving a mean Cmax of 1,032 ng/ml and a mean AUC0-48h of 42,857 ng·h/ml.
U pacijenata s bolešću bubrega u završnoj fazi (CrCl &lt; 10 ml/min) kojima je potrebna hemodijaliza koncentracije tenofovira između dijaliza znatno su se povećale tijekom 48 sati i dosegle srednju vrijednost Cmax od 1032 ng/ml i srednju vrijednost AUC0-48h od 42.857 ng·h/ml.
In patients with end-stage renal disease receiving dialysis, single doses of immediate-release exenatide increased frequency and severity of gastrointestinal adverse reactions; therefore, prolonged-release exenatide is not recommended for use in patients with end-stage renal disease or severe renal impairment (creatinine clearance &lt; 30 ml/min).
U bolesnika u završnom stadiju bubrežne bolesti koji su na dijalizi, jednokratne doze eksenatida s trenutnim oslobađanjem povećale su učestalost i težinu gastrointestinalnih nuspojava; stoga se ne preporučuje primjena eksenatida s produljenim oslobađanjem u bolesnika u završnom stadiju bubrežne bolesti ili u bolesnika s teškim oštećenjem bubrega (klirens kreatinina &lt; 30 ml/min).
In patients with factor VII deficiency, where the recommended dose is 15 – 30 µg/kg rFVIIa, one episode of overdose has been associated with a thrombotic event (occipital stroke) in an elderly ( &gt; 80 year) male patient treated with 10 – 20 times the recommended dose.
U bolesnika s nedostatkom faktora VII, gdje je preporučena doza rFVIIa 15 - 30 µg/kg, jedan slučaj predoziranja bio je povezan s trombozom (okcipitalni moždani udar) u starijeg ( &gt; 80 godina) muškog bolesnika liječenog 10 - 20 puta većom dozom od preporučene.
In patients with granulomatosis with polyangiitis or microscopic polyangiitis, the number of peripheral blood B cells decreased to &lt; 10 cells/μL after two weekly infusions of rituximab 375 mg/m2, and remained at that level in most patients up to the 6 month timepoint.
U bolesnika s granulomatozom s poliangitisom i mikroskopskim poliangitisom broj perifernih B stanica smanjio se na &lt; 10 stanica/µl nakon dvije tjedne infuzije rituksimaba u dozi od 375 mg/m2 i održao na toj razini u većine bolesnika do trenutka mjere ishoda nakon 6 mjeseci.
In patients with high viral load ( &gt; 100,000 copies/ml) choice of therapy needs special consideration (see section 5.1).
Potrebna je posebna pažnja pri razmatranju odabira terapije u bolesnika s visokim virusnim opterećenjem ( &gt; 100 000 kopija/ml) (vidjeti dio 5.1).
In patients with high viral load ( &gt; 100,000 copies/ml) the choice of a triple combination with abacavir, lamivudine and zidovudine needs special consideration (see section 5.1).
U bolesnika s velikim brojem kopija virusa ( &gt; 100 000 kopija/ml) treba posebno razmotriti mogućnost izbora trostruke terapije (abakavir, lamivudin i zidovudin) (vidjeti dio 5.1).
In patients with lower body weights ( &lt; 59 kg, the lowest body weight quartile) the fixed dose used in the Herceptin subcutaneous arm was not associated with an increased risk of cardiac events or significant drop in LVEF.
U bolesnika manje tjelesne težine ( &lt; 59 kg, najniži kvartil tjelesne težine), fiksna doza koja se primjenjivala u skupini liječenoj lijekom Herceptin za supkutanu primjenu nije bila povezana s povećanim rizikom od srčanih događaja niti značajnim padom LVEF-a.
In patients with mild or moderate renal impairment (creatinine clearance  30–80 ml/min) compared to those with normal renal function (creatinine clearance &gt; 80 ml/min), the most commonly reported events and their placebo-corrected frequencies included: constipation (8% versus 4%), dizziness (7% versus 5%), and nausea (4% versus 2%).
Kod bolesnika s blago ili umjereno oštećenom funkcijom bubrega (klirens kreatinina  30–80 ml/min) u usporedbi s bolesnicima s normalnom funkcijom bubrega (klirens kreatinina &gt; 80 ml/min), najčešće zabilježene nuspojave i njihove učestalosti korigirane u odnosu na placebo uključivale su: konstipaciju (8% u odnosu na 4%), omaglicu (7% u odnosu na 5%) i mučninu (4% u odnosu na 2%).
In patients with mild or moderate renal impairment a loading dose of 200 mg may be considered but further dose titration ( &gt; 200 mg daily) should be performed with caution.
Kod bolesnika s blagim ili umjerenim oštećenjem bubrega može se razmotriti mogućnost udarne doze od 200 mg, ali daljnju titraciju doze ( &gt; 200 mg dnevno) treba provoditi s oprezom.
In patients with mild or moderate renal impairment a loading dose of 200 mg may be considered, but further dose titration ( &gt; 200 mg daily) should be performed with caution.
Kod bolesnika s blagim ili umjerenim oštećenjem bubrega može se razmotriti mogućnost udarne doze od 200 mg, ali daljnju titraciju doze ( &gt; 200 mg dnevno) treba provoditi s oprezom.
In patients with mild renal impairment (CrCL &gt; 50 – 80 mL/min), the recommended dose is 60 mg Lixiana once daily.
Za bolesnike s blagim oštećenjem funkcije bubrega (CrCL &gt; 50 – 80 ml/min), preporučena doza Lixiane je 60 mg jedanput na dan.
In patients with mild renal impairment (estimated creatinine clearance [CrCL] &gt; 50 mL/min), no dose adjustment is necessary, see section 5.2).
U bolesnika s blagim oštećenjem funkcije bubrega (procijenjeni klirens kreatinina [CrCl] &gt; 50 ml/min) nije potrebno prilagođavati dozu (vidjeti dio 5.2).
In patients with mild, moderate or severe renal impairment (eGFR &lt; 30 - &lt; 90 ml/min/1.73 m2) and patients with kidney failure/end stage renal disease (ESRD), AUC of empagliflozin increased by approximately 18%, 20%, 66%, and 48%, respectively compared to subjects with normal renal function.
U bolesnika s blagim, umjerenim ili teškim oštećenjem bubrega (eGFR &lt; 30 do &lt; 90 ml/min/1,73 m2) i bolesnika sa zatajenjem bubrega/terminalnim stadijem bolesti bubrega (ESRD), AUC empagliflozina se povećao za približno 18%, 20%, 66% odnosno 48% u usporedbi s ispitanicima s normalnom bubrežnom funkcijom.
In patients with moderate (Creatinine Clearance (CrCl) ≥ 30 and &lt; 50 ml/min), severe renal impairment (CrCL &gt; 15 and &lt; 30 ml/min) and End Stage Renal Disease (ESRD) patients (CrCl &lt; 15 ml/min), the recommended starting dose is 18.5 mg and the maximum dose should not exceed 74 mg once daily.
U bolesnika s umjerenim (klirens kreatinina (CrCl) ≥ 30 i &lt; 50 ml/min), teškim bubrežnim oštećenjem (CrCl &gt; 15 i &lt; 30 ml/min) i završnim stadijem bubrežne bolesti kod kojih je CrCl &lt; 15 ml/min), preporučena početna doza je 18,5 mg, dok najviša doza ne smije prelaziti 74 mg jednom dnevno.
In patients with moderate hepatic impairment (total bilirubin &gt; 1.5 to ≤ 3.0 x ULN), the maximum tolerated dose (MTD) was 15 mg/m2.
Kod bolesnika s umjerenim oštećenjem jetrene funkcije (ukupan bilirubin &gt; 1,5 do ≤ 3,0 x GGN), najviša podnošljiva doza bila je 15 mg/m2.
In patients with moderate hypercalcaemia (albumin- corrected serum calcium &lt; 3 mmol/l or &lt; 12 mg/dl) 2 mg is an effective dose.
U bolesnika s umjerenom hiperkalcijemijom (kalcij u serumu korigiran albuminom &lt; 3 mmol/l ili &lt; 12 mg/dl) doza od 2 mg je učinkovita.
In patients with moderate hypercalcaemia (albumin-corrected serum calcium &lt; 3 mmol/l or &lt; 12 mg/dl) 2 mg is an effective dose.
U bolesnika s umjerenom hiperkalcijemijom (kalcij u serumu korigiran albuminom &lt; 3 mmol/l ili &lt; 12 mg/dl) doza od 2 mg je učinkovita.
In patients with moderate or severe renal impairment (creatinine clearance &lt; 50 ml/min) the daily dose must be adjusted and renal function should be closely monitored (see sections 4.2 and 5.2).
U pacijenta s umjerenim ili teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 50 ml/min) dnevna doza mora se prilagoditi, a funkcija bubrega detaljno pratiti (vidjeti dijelove 4.2 i 5.2).
In patients with moderate or severe renal impairment (creatinine clearance &lt; 50 mL/min), accumulation of the intravenous vehicle, Betadex Sulfobutyl Ether Sodium (SBECD), is expected to occur.
U bolesnika s umjerenim ili teškim oštećenjem funkcije bubrega (klirens kreatinina &lt; 50 ml/min) očekuje se nakupljanje intravenskog vehikuluma, natrijeva sulfobutileter β-ciklodekstrina (SBECD).
In patients with moderate renal impairment (estimated creatinine clearance  30 ml/min and  50 ml/min), varenicline exposure increased 1.5- fold compared with subjects with normal renal function (estimated creatinine clearance &gt; 80 ml/min).
U bolesnika s umjerenim oštećenjem bubrežne funkcije (procijenjeni klirens kreatinina ≥ 30 ml/min i ≤ 50 ml/min) izloženost vareniklinu povećala se 1,5 puta u usporedbi s ispitanicima s normalnom bubrežnom funkcijom (procijenjeni klirens kreatinina &gt; 80 ml/min).
In patients with moderate to severe renal dysfunction (creatinine clearance &lt; 50 ml/min), accumulation of the intravenous vehicle, SBECD, occurs.
U bolesnika s umjerenom do teškom disfunkcijom bubrega (klirens kreatinina &lt; 50 ml/min) dolazi do kumulacije intravenskog vehikuluma (natrijevog sulfobutileter -ciklodekstrina (SBECD)).
In patients with moderate to severe renal dysfunction (creatinine clearance &lt; 50 ml/min), accumulation of the intravenous vehicle, SBECD, occurs.
U bolesnika s umjerenom do teškom disfunkcijom bubrega (klirens kreatinina &lt; 50 ml/min), dolazi do kumulacije intravenskog vehikuluma, natrijevog sulfobutileter beta ciklodekstrina (SBECD).
In patients with moderate to severe renal dysfunction (serum creatinine levels &gt; 2.5 mg/dl), accumulation of the intravenous vehicle, SBECD, occurs (see sections 4.2 and 4.4).
U bolesnika s umjerenom do teškom disfunkcijom bubrega (razine kreatinina u serumu &gt; 2,5 mg/dl) dolazi do kumulacije intravenskog vehikuluma SBECD-a (vidjeti dijelove 4.2 i 4.4).
In patients with moderate to severe renal dysfunction (serum creatinine levels &gt; 2.5 mg /dl), accumulation of the intravenous vehicle, SBECD, occurs (see sections 4.2 and 4.4).
U bolesnika s umjerenom do teškom disfunkcijom bubrega (razine kreatinina u serumu &gt; 2,5 mg/dl) dolazi do kumulacije intravenskog vehikuluma, SBECD-a (vidjeti dijelove 4.2 i 4.4).
In patients with moderate to severe renal insufficiency (creatinine clearance &lt; 50 ml/min), the clearance of eptifibatide is reduced by approximately 50 % and steady-state plasma levels are approximately doubled.
U bolesnika s umjerenim do teškim oštećenjem bubrega (klirens kreatinina &lt; 50 ml/min), klirens eptifibatida smanjuje se za oko 50 %, a koncentracije u plazmi u stanju dinamičke ravnoteže su približno udvostručene.
In patients with moderate to severe renal insufficiency (creatinine clearance &lt; 50 ml/min), the clearance of eptifibatide is reduced by approximately 50% and steady-state plasma levels are approximately doubled.
U bolesnika s umjerenim do teškim oštećenjem bubrega (klirens kreatinina &lt; 50 ml/min), klirens eptifibatida smanjuje se za oko 50 %, a koncentracije u plazmi u stanju dinamičke ravnoteže su približno udvostručene.
In patients with normal renal function (creatinine clearance &gt; 80 mL/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1600 mg/day) and acetylsalicylic acid at higher dose ( &gt; 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen &gt; 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu nuspojava izazvanih pemetreksedom.
In patients with normal renal function (creatinine clearance &gt; 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1600 mg/day) and aspirin at higher dose ( &gt; 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom bubrežnom funkcijom (klirens kreatinina &gt; 80 ml/min), visoke doze nesteroidnih protuupalnih lijekova (NSAIL, poput ibuprofena &gt; 1600 mg/dan) i više doze acetilsalicilatne kiseline ( &gt; 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavnost nuspojava pemetrekseda.
In patients with normal renal function (creatinine clearance &gt; 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1600 mg/day) and aspirin at higher dose ( &gt; 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen &gt; 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu nuspojava izazvanih pemetreksedom.
In patients with normal renal function (creatinine clearance &gt; 80 ml/min), high doses of non-steroidal anti-inflammatory medicinal product (NSAIDs, such as ibuprofen &gt; 1600 mg/day) and aspirin at higher dose ( &gt; 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, poput ibuprofena &gt; 1600 mg na dan) i više doze aspirina (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu štetnih događaja izazvanih pemetreksedom.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1,600 mg/day) and aspirin at higher dose (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen &gt; 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu nuspojava izazvanih pemetreksedom.
In patients with normal renal function (creatinine clearance ≥ 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen &gt; 1600 mg/day) and aspirin at higher doses (≥ 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
U bolesnika s normalnom funkcijom bubrega (klirens kreatinina ≥ 80 ml/min) visoke doze nesteroidnih protuupalnih lijekova (NSAIL, npr. ibuprofen &gt; 1600 mg na dan) i više doze acetilsalicilatne kiseline (≥ 1,3 g na dan) mogu smanjiti eliminaciju pemetrekseda i, posljedično povećati pojavu nuspojava izazvanih pemetreksedom.